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Children in the child welfare system are given psychotro-pic medication at rates approximately three times higher than children and adolescents in the general population. 
Psychotropic medication refers to drugs prescribed to affect 
the mind, emotions, and behavior. Previous research finds that 
14 percent of children in the child protective system—which 
includes children who had a report of suspected maltreatment 
and includes those in foster care, kinship care, and children who 
remained in their home after the investigation of child abuse—
were prescribed psychotropic medications from 2001–2002.1 
In contrast, Medicaid data suggest that 5 percent to 6 percent 
of low-income children were prescribed psychotropic medica-
tion, and prior research suggests rates of 4 percent to 6 percent 
among children and adolescents in the general population.2 A 
recent report by the General Accountability Office (GAO) finds 
that between 20 percent and 39 percent of foster children in five 
states (Florida, Massachusetts, Michigan, Oregon, and Texas) 
were prescribed psychotropic drugs compared with between 5 
percent and 10 percent of children receiving Medicaid in those 
states.3 Studies suggest that white race/ethnicity, male gender, 
older age, history of physical and sexual abuse, foster care (ver-
sus in-home), and need for mental health services are all cor-
related with medication use among child welfare populations.4
In some respect, these high rates among children in the child 
welfare system are not surprising. Nationally, nearly one-half of 
children in contact with child welfare agencies have clinically 
significant emotional or behavioral problems.5 Furthermore, 
from the mid-1980s to the mid-1990s, psychotropic medication 
prescriptions among children in general increased two- to three-
fold,6 with rates continuing to increase in the 2000s.7 
Variations in rates of prescription by location raise some 
concerns. One study found that children living in the South 
were more likely to receive stimulants than those living in 
other areas of the country.8 Another study found that children 
in mostly rural and mostly urban areas were more likely to 
receive stimulants than were those living in fully rural areas. 
The geographic variation remained after controlling for child 
age and gender.9 There was no difference in use between 
 
 Key Findings
•	 Among children age 4 and older with a report of 
maltreatment, rates of psychotropic medication 
use are significantly higher in rural (20 percent) 
than urban areas (13 percent). 
•	 Children age 4 and older with a maltreatment 
report in rural areas were significantly more likely 
to take more than one medication than children 
in urban areas. In rural places, 28 percent took two 
medications and 33 percent took three or more 
medications. In urban places, 23 percent took two 
and 14 percent took three or more medications.
•	 In addition to emotional or behavioral problems, 
a number of other factors predicted which 
children were given psychotropic medication, 
including whether they receive counseling, being 
12 years old or older, and being male.
•	 In rural places, children living in poor households 
were more likely to be given psychotropic 
medication.
•	 Twenty percent of children in rural areas with a 
child maltreatment report who remain in-home 
received medication compared to 12 percent in 
urban areas.
Psychotropic Medication Use Among Children in 
the Child Welfare System 
W E N D Y  A .  WA L S H  A N D  M A R Y B E T H  J .  M A T T I N G L Y
children living in fully rural and fully urban areas, and physi-
cian supply rate (that is, the number of physicians by area) was 
not significantly associated with use. Two other small studies 
found no differences in stimulant use in rural or urban areas.10 
Likewise, results from studies focusing only on children in the 
child welfare system vary by location. For example, one study 
found that only 7 percent of California children in the child 
welfare system were taking psychotropic medications while 20 
percent of such children in Texas were.11 Another study found 
rates varied between 0 percent and 40 percent across a variety of 
locations.12 Both studies found few contextual factors (such as 
Medicaid generosity, per capita rate of psychiatrists, or county 
poverty rates, among others) predicted medication use. Instead, 
child characteristics were more important predictors. 
Thus, place appears to be important in determining whether 
children involved with the child welfare system receive psy-
chotropic medication. Therefore, understanding psychotropic 
medication use in rural versus urban areas can help determine 
if some children disproportionally receive medical, rather than 
other, interventions in rural or urban areas and provide a bet-
ter understanding of need, which can contribute to meaningful 
policy and resource allocation discussions.
 
Psychotropic Medication Use 
Using data from the second National Survey of Child and 
Adolescent Well-Being (NSCAW II), we find that among 
children age 4 and older with a maltreatment report, rates 
of psychotropic medication use are significantly higher in 
rural than urban areas (see Figure 1).13 Twenty percent of 
children with a maltreatment report in rural areas currently 
receive medication compared with 13 percent of those in 
urban areas. More rural children have also ever been given 
psychotropic medication: 27 percent of children with a mal-
treatment report in rural areas had ever received medication 
compared with 19 percent of those in urban areas. 
Children with a maltreatment report receiving medication 
Figure 1. Psychotropic medication use by place, 
among children 4 and older with a child  
maltreatment report
in rural areas were significantly more likely to take multiple 
medications than were those in urban areas (see Figure 2). 
Specifically, in rural places, 33 percent of children were given 
three or more medications compared with 14 percent of chil-
dren in urban places.
Figure 2. Number of Psychotropic Medications  
by Place
Need for Psychotropic Medication
Nationally, an estimated 42 percent of children with a maltreat-
ment report who also have emotional/behavioral problems 
take psychotropic medication, with no differences in use of 
medication in rural or urban areas. Children with a maltreat-
ment report in rural areas were significantly more likely to have 
a diagnosis of ADD/ADHD at the time of the maltreatment 
investigation (28 percent) than were children in urban areas (20 
percent) (see Figure 3). However, there was no difference in use 
when examining only the group of children with ADD/ADHD. 
There were no other significant diagnostic differences by place. 
Overall, the most common diagnosis was ADD/ADHD (22 
percent), followed by an emotional problem (19 percent), devel-
opmental delay (5 percent), and autism (3 percent). 
Figure 3. Emotional or behavioral problems 
among children 4 and older with a child  
maltreatment report
Note: An asterisk (*) indicates statistically significant differences (p<0.05).
Source: NSCAW II
Note: An asterisk (*) indicates statistically significant differences (p<0.05).
Source: NSCAW II
Note: An asterisk (*) indicates statistically significant differences (p<0.05).
Source: NSCAW II
  2 C A R S E Y  I N S T I T U T E
Characteristics of Children  
Receiving Medication
There were several significant differences in the characteristics 
of children receiving medication in rural and urban places 
(see Table 1). In rural places, children with a maltreatment 
report receiving medication were significantly more likely 
than those in urban places to be:
•	 Older: 36 percent of children aged 12–17 in rural 
places with a maltreatment report receive medication 
versus 12 percent in urban places.
•	 Girls: 19 percent of girls in rural places with a mal-
treatment report receive medication versus 8 percent 
in urban places.
•	 Living at home after the child abuse investigation (that 
is, not removed because of concerns for safety): 20 
percent of children with a maltreatment report who are 
living at home in rural places receive medication versus 
12 percent in urban places.
•	 Poor: 29 percent of rural children with a maltreatment 
report and living in poor households—whose income is 
50 percent to 100 percent of the federal poverty level—
receive medication versus 12 percent in urban places. 
There was no difference across rural and urban areas 
in receiving medication by race/ethnicity or whether the 
child received counseling. About 21 percent of white chil-
dren received medication in both rural and urban areas, 
and 10 percent of minority children received medication 
in both rural and urban areas. Nearly one-half of children 
receiving counseling in both rural and urban areas were 
also taking psychotropic medications.
To understand the impact of these characteristics in 
rural versus urban places, we conducted a multivari-
ate logistic regression model. This analysis simultane-
ously accounts for many possible factors and determines 
the probability of psychotropic medication use for each 
individual factor net of the others. This type of analysis is 
important because it accounts for factors that tend to co-
occur. Children with an emotional or behavioral problem 
had the highest probability of psychotropic medication 
use.14 Children who receive counseling, children who are 
12 years old or older, and boys had higher probabilities of 
psychotropic medication use, net of other factors. 
Because characteristics of children on medication in 
rural and urban areas differed, we also included four 
interaction terms in the regression (rural and poor, rural 
and child aged 12 or older, rural and boy, and rural and 
out-of-home placement). This is important because 
it allows us to examine the association of psychotro-
pic medication use for these particular characteristics, 
controlling for other factors. Even accounting for other 
characteristics, rural children living in poor households 
(less than 100 percent of federal poverty), and those aged 
12 and older had higher probabilities of receiving psycho-
tropic medication than their urban peers. 
Understanding Psychotropic Medica-
tion Use in Rural and Urban Places
The significantly higher rates of psychotropic medication 
use among children in rural areas and the significantly 
higher rates of taking multiple medications point to the need 
among child welfare professionals in rural areas to closely 
monitor use. There were several significant differences in the 
characteristics of children receiving medication in rural and 
urban places. In rural places, children receiving medication 
were more likely to be older, girls, living at home, and poor 
compared to those receiving medication in urban places. 
When used appropriately medications can provide a viable 
treatment option. However, it is generally recommended that 
prescriptions be closely monitored, especially when children 
are prescribed more than one medication.15 
A number of factors may play a role in the patterns of 
psychotropic medication use in the child welfare system, 
including:16
Table 1. Characteristics of children 4 and older 
with a child maltreatment report receiving 
medication by place
Note: An asterisk (*) indicates statistically significant differences (p<0.05).
Source: NSCAW II
 C A R S E Y  I N S T I T U T E  3
•	 Insufficient state oversight and monitoring of psycho-
tropic medication use 
•	 Gaps in coordination and continuity of medical and 
mental health care across public health and social 
service systems 
•	 Provider shortages, especially of board-eligible and 
board-certified child and adolescent psychiatrists, 
especially in rural areas 
•	 Lack of access to effective nonpharmacological 
treatments in outpatient settings
The Administration on Children, Youth, and Families 
(ACF) has focused on the social and emotional well-being 
among children involved in foster care.17 For example, a 
new requirement mandated in the Child and Family Service 
Improvement and Innovation Act (P.L. 112-34) requires states 
to include a psychotropic medication oversight plan in their 
“State Child and Family Service Plans” when children enter 
out-of-home care.18 Given the high rates of use, this is encour-
aging oversight. However, this requirement does not address 
psychotropic medication use among children who remain in 
their home. Given that 20 percent of children in rural areas 
with a child maltreatment report who remain in-home are 
receiving medication, it would be beneficial for child welfare 
professionals and pediatricians to help educate parents about 
access to both pharmacological and nonpharmacological 
behavioral treatments. Doing so can help ensure that chil-
dren in need are receiving appropriate services. Because rates 
of counseling did not differ across place type, it will still be 
important to maintain or enhance access to nonpharmacolog-
ical treatment across rural and urban America. Although we 
did not explore the topic here, future research should consider 
how the quality of services might differ across place. 
Much more information is needed to better understand 
the use and impact of such medication. For example, few 
studies have examined the safe and appropriate pediatric 
use of psychotropic medication,19 and there is even less 
evidence of the effectiveness of pharamacologic interven-
tions for treating trauma-related symptoms in children.20 In 
the absence of such research, it is not possible to adequately 
assess the positive and negative short- and long-term effects 
of psychotropic medication use.21 
Medication can be an important component of a com-
prehensive response to the mental health needs of children. 
However, as described in the recent memorandum by the 
ACF, current use of psychotropic medications among children 
in foster care and among the child welfare population may 
exceed practice standards.22 The memorandum emphasizes that 
greater oversight of psychotropic medication is necessary, with 
enhanced collaboration among child welfare agencies, families, 
and professionals and organizations providing mental health 
services. The results of the current analysis indicate that more 
information is needed about the complex decision-making 
process regarding medication use. This includes a need to better 
understand how who ultimately decides may make a difference 
in use, how pediatric clinicians make decisions, and the impact 
of community norms on medication use.23 The results presented 
here provide a first step in increasing awareness about char-
acteristics of children receiving medication. This information 
may help professionals working with children involved with the 
child welfare system and ensure that effective treatment plans 
are in place for children.
Data
All fifty states, the District of Columbia, and U.S. Territories 
have mandatory child abuse and neglect reporting laws that 
require certain professionals and institutions to report sus-
pected maltreatment to a child protection services (CPS) 
agency. CPS then investigates the reports of suspected maltreat-
ment. The data for this analysis come from a national sample 
of children who had a maltreatment report that resulted in 
an investigation: the second National Survey of Child and 
Adolescent Well-Being (NSCAW II). It includes both substanti-
ated cases, cases with sufficient evidence to determine that child 
maltreatment has occurred, and unsubstantiated cases, cases in 
which maltreatment cannot be substantiated. The NSCAW II 
study design mirrors that of NSCAW I, which collected data on 
children involved with CPS beginning in 1999. The NSCAW 
II cohort includes 5,873 children, aged birth to 17.5 years old, 
who had contact with the child welfare system within a fifteen-
month period beginning in February 2008. A two-staged 
cluster sampling strategy was used. Information on the NSCAW 
II study design and sampling procedure has been previously 
published.24 Face-to-face interviews were conducted with chil-
dren, parents, and nonparent adult caregivers and investigative 
caseworkers. Statistics were computed using survey weights to 
account for the complex sampling design of NSCAW. All dif-
ferences discussed are statistically significant at the 95 percent 
confidence level (p < .05).
The sample for this analysis included 2,561 children aged 
4 to 17.5 years old because initial analysis indicated psy-
chotropic medication typically began at age 4 (only three 
children younger than age 4 were on medication). Most of 
the children in the sample (87 percent) were living at home; 
13 percent were living out-of-home.
The urbanicity of the primary sampling unit (PSU)/
county was calculated using the Census Bureau definitions 
for the entire county/PSU. Urban was defined as greater than 
50 percent of the population living in an urban area, whereas 
nonurban/rural was defined as all areas that did not meet 
this requirement. 
A few caveats should be mentioned. NSCAW’s data confi-
dentiality agreements preclude analysis by county. Therefore, 
our analysis focused on the urbanicity of the area served by the 
child welfare agency. However, it could be that the impact of 
urbanicity may vary by the state. We did not have information 
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about the experience or training of the prescriber, which could 
likely affect rates. We also lacked information on whether use is 
indicative of appropriate or inappropriate use. Future research 
should consider some of these additional considerations of use. 
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Definitions
Current use of psychotropic medication is indicated 
when a caregiver answered yes to “Is child currently tak-
ing any medication for emotional or behavioral prob-
lems?” Ever using psychotropic medication is indicated 
when a caregiver answered yes to “To your knowledge, 
has child ever taken any medication prescribed by a doc-
tor or clinician for emotional or behavioral problems?” 
Emotional or behavior problems are indicated when a 
caregiver answered yes to whether their child has atten-
tion deficit disorder or attention deficit hyperactivity 
disorder (ADD or ADHD); autism, autism spectrum 
disorder (ASD); mental retardation or developmental 
delay; or depression, anxiety, an eating disorder, or other 
emotional problems.
Any counseling services are indicated when a caregiver 
answered yes to their child receiving counseling services 
at a mental health community center, private practice, or 
in-home counseling services in the past twelve months.
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